Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(-89.9%)
USD 0.0
(-89.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.51 Million USD | 60.68% |
| 2022 | -24.2 Million USD | 3.78% |
| 2021 | -25.15 Million USD | -65.31% |
| 2020 | -15.21 Million USD | 35.09% |
| 2019 | -23.44 Million USD | -109.64% |
| 2018 | -11.18 Million USD | 28.15% |
| 2017 | -15.56 Million USD | 8.88% |
| 2016 | -17.08 Million USD | 48.71% |
| 2015 | -33.3 Million USD | 14.77% |
| 2014 | -39.07 Million USD | -62.63% |
| 2013 | -24.02 Million USD | -103.23% |
| 2012 | -11.82 Million USD | -6.17% |
| 2011 | -11.13 Million USD | -66.07% |
| 2010 | -6.7 Million USD | -30552.91% |
| 2009 | -21.87 Thousand USD | 25.18% |
| 2008 | -29.23 Thousand USD | -0.79% |
| 2007 | -29 Thousand USD | -2788.65% |
| 2006 | -1004.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -9.51 Million USD | 60.68% |
| 2023 Q2 | -1.37 Million USD | 67.97% |
| 2023 Q1 | -4.28 Million USD | -39.08% |
| 2023 Q3 | -1.22 Million USD | 10.36% |
| 2023 Q4 | -2.21 Million USD | -80.23% |
| 2022 Q3 | -4.95 Million USD | 37.1% |
| 2022 Q1 | -8.3 Million USD | -33.37% |
| 2022 FY | -24.2 Million USD | 3.78% |
| 2022 Q4 | -3.07 Million USD | 37.86% |
| 2022 Q2 | -7.87 Million USD | 5.14% |
| 2021 Q4 | -6.22 Million USD | -61.62% |
| 2021 Q3 | -3.85 Million USD | -4.85% |
| 2021 Q1 | -3.81 Million USD | 2.35% |
| 2021 Q2 | -3.67 Million USD | 3.82% |
| 2021 FY | -25.15 Million USD | -65.31% |
| 2020 Q2 | -2.6 Million USD | 56.82% |
| 2020 FY | -15.21 Million USD | 35.09% |
| 2020 Q1 | -6.02 Million USD | 15.74% |
| 2020 Q3 | -3.3 Million USD | -27.0% |
| 2020 Q4 | -3.91 Million USD | -18.44% |
| 2019 Q3 | -5.17 Million USD | -44.43% |
| 2019 FY | -23.44 Million USD | -109.64% |
| 2019 Q4 | -7.14 Million USD | -38.15% |
| 2019 Q2 | -3.58 Million USD | -33.83% |
| 2019 Q1 | -2.67 Million USD | -5.48% |
| 2018 Q3 | -1.94 Million USD | 38.01% |
| 2018 Q4 | -2.53 Million USD | -30.77% |
| 2018 FY | -11.18 Million USD | 28.15% |
| 2018 Q1 | -3.56 Million USD | 25.77% |
| 2018 Q2 | -3.12 Million USD | 12.24% |
| 2017 Q2 | -4.69 Million USD | -56.18% |
| 2017 FY | -15.56 Million USD | 8.88% |
| 2017 Q4 | -4.8 Million USD | -56.72% |
| 2017 Q3 | -3.06 Million USD | 34.64% |
| 2017 Q1 | -3 Million USD | -1.86% |
| 2016 FY | -17.08 Million USD | 48.71% |
| 2016 Q4 | -2.94 Million USD | 11.83% |
| 2016 Q2 | -4.36 Million USD | 31.99% |
| 2016 Q1 | -6.42 Million USD | 37.69% |
| 2016 Q3 | -3.34 Million USD | 23.44% |
| 2015 Q4 | -10.3 Million USD | -34.36% |
| 2015 Q2 | -7.72 Million USD | -1.61% |
| 2015 Q1 | -7.59 Million USD | 25.19% |
| 2015 Q3 | -7.67 Million USD | 0.64% |
| 2015 FY | -33.3 Million USD | 14.77% |
| 2014 Q2 | -8.94 Million USD | 14.65% |
| 2014 Q4 | -10.15 Million USD | -6.96% |
| 2014 Q3 | -9.49 Million USD | -6.23% |
| 2014 FY | -39.07 Million USD | -62.63% |
| 2014 Q1 | -10.47 Million USD | -38.98% |
| 2013 FY | -24.02 Million USD | -103.23% |
| 2013 Q2 | -6.45 Million USD | -58.02% |
| 2013 Q3 | -5.94 Million USD | 7.95% |
| 2013 Q4 | -7.53 Million USD | -26.82% |
| 2013 Q1 | -4.08 Million USD | -8.75% |
| 2012 Q4 | -3.75 Million USD | -34.15% |
| 2012 FY | -11.82 Million USD | -6.17% |
| 2012 Q3 | -2.8 Million USD | -23.59% |
| 2012 Q2 | -2.26 Million USD | 24.37% |
| 2012 Q1 | -2.99 Million USD | 34.15% |
| 2011 Q4 | -4.55 Million USD | -64.28% |
| 2011 Q1 | -2.23 Million USD | -35.68% |
| 2011 FY | -11.13 Million USD | -66.07% |
| 2011 Q3 | -2.76 Million USD | -75.68% |
| 2011 Q2 | -1.57 Million USD | 29.53% |
| 2010 Q1 | -1.47 Million USD | -32427.09% |
| 2010 Q2 | -1.14 Million USD | 22.68% |
| 2010 Q3 | -2.43 Million USD | -112.75% |
| 2010 Q4 | -1.64 Million USD | 32.22% |
| 2010 FY | -6.7 Million USD | -30552.91% |
| 2009 FY | -21.87 Thousand USD | 25.18% |
| 2009 Q1 | -9704.00 USD | -131.82% |
| 2009 Q4 | -4547.00 USD | -15.11% |
| 2009 Q3 | -3950.00 USD | -7.6% |
| 2009 Q2 | -3671.00 USD | 62.17% |
| 2008 Q2 | -2697.00 USD | 81.7% |
| 2008 Q3 | -6376.00 USD | -136.41% |
| 2008 Q4 | -4186.00 USD | 34.35% |
| 2008 FY | -29.23 Thousand USD | -0.79% |
| 2008 Q1 | -14.74 Thousand USD | -134.53% |
| 2007 Q4 | -6285.00 USD | 14.2% |
| 2007 Q1 | -300.00 USD | -19.52% |
| 2007 Q2 | -15.09 Thousand USD | -4930.67% |
| 2007 FY | -29 Thousand USD | -2788.65% |
| 2007 Q3 | -7325.00 USD | 51.46% |
| 2006 FY | -1004.00 USD | 0.0% |
| 2006 Q4 | -251.00 USD | 0.0% |
| 2006 Q3 | -251.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 70.178% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 76.723% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 81.668% |
| Azitra, Inc. | -7.61 Million USD | -24.967% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -16.144% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -38.7% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 67.17% |
| CEL-SCI Corporation | -31.47 Million USD | 69.761% |
| iBio, Inc. | -16.63 Million USD | 42.78% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 61.517% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 52.84% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 59.951% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 32.261% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -90.246% |
| NanoViricides, Inc. | -8.51 Million USD | -11.765% |
| Oragenics, Inc. | -20.9 Million USD | 54.47% |
| BiomX Inc. | -27.68 Million USD | 65.62% |
| BiomX Inc. | -27.68 Million USD | 65.62% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 190.994% |
| Palatin Technologies, Inc. | -22.49 Million USD | 57.69% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 77.355% |
| Theriva Biologics, Inc. | -21.43 Million USD | 55.588% |